Akebia Therapeutics Inc. (AKBA) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Akebia Therapeutics Inc.

    NASDAQ: AKBA · Real-Time Price · USD
    2.74
    0.03 (1.11%)
    At close: Sep 26, 2025, 3:59 PM
    2.76
    0.71%
    After-hours: Sep 26, 2025, 07:54 PM EDT

    Akebia Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 160.18M 194.62M 292.6M 213.58M
    Cost of Revenue
    		 63.18M 74.15M 84.8M 153.39M
    Gross Profit
    		 97M 120.47M 207.81M 60.18M
    Operating Income
    		 -50.47M -46.26M -63.18M -265.32M
    Interest Income
    		 n/a n/a n/a n/a
    Pretax Income
    		 -69.41M -51.92M -92.56M -282.84M
    Net Income
    		 -69.41M -51.92M -106.01M -244.87M
    Selling & General & Admin
    		 106.55M 100.23M 138.6M 174.14M
    Research & Development
    		 37.65M 63.08M 129.11M 147.85M
    Other Expenses
    		 40.31M 3.42M -12.54M 3.49M
    Operating Expenses
    		 184.5M 166.73M 270.99M 325.5M
    Interest Expense
    		 18.18M 6.03M 15.69M 19.94M
    Selling & Marketing Expenses
    		 4.6M 100.23M 6.7M 8.2M
    Cost & Expenses
    		 210.65M 240.88M 355.78M 478.9M
    Income Tax Expense
    		 n/a n/a 13.45M -37.97M
    Shares Outstanding (Basic)
    		 210.95M 187.47M 182.78M 165.95M
    Shares Outstanding (Diluted)
    		 210.95M 187.47M 182.78M 165.95M
    EPS (Basic)
    		 -0.33 -0.28 -0.58 -1.48
    EPS (Diluted)
    		 -0.33 -0.28 -0.58 -1.48
    EBITDA
    		 -13.72M -6.87M -43.26M -225.96M
    EBIT
    		 -51.23M -45.89M -78.54M -262.09M
    Depreciation & Amortization
    		 37.5M 37.63M 35.28M 36.13M

    Add to Watchlist